TearLab Corp (TEAR) Getting Somewhat Negative News Coverage, AlphaOne Reports

News coverage about TearLab Corp (NASDAQ:TEAR) has trended somewhat negative this week, according to Alpha One Sentiment. Alpha One, a division of Accern, scores the sentiment of media coverage by reviewing more than 20 million blog and news sources in real time. Alpha One ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. TearLab Corp earned a daily sentiment score of -0.12 on Alpha One’s scale. Alpha One also gave news articles about the medical research company an impact score of 94 out of 100, meaning that recent media coverage is extremely likely to have an impact on the company’s share price in the near term.

These are some of the media stories that may have effected AlphaOne Sentiment Analysis’s analysis:

Shares of TearLab Corp (NASDAQ:TEAR) opened at 2.12 on Friday. The company’s 50-day moving average price is $2.25 and its 200 day moving average price is $4.40. TearLab Corp has a 1-year low of $1.85 and a 1-year high of $9.00. The company’s market cap is $11.38 million.

TearLab Corp (NASDAQ:TEAR) last announced its quarterly earnings data on Monday, May 15th. The medical research company reported ($0.82) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.75) by $0.07. The company had revenue of $6.70 million for the quarter, compared to the consensus estimate of $7.02 million. During the same period in the previous year, the company posted ($0.21) earnings per share. The company’s quarterly revenue was down 1.5% compared to the same quarter last year. On average, analysts predict that TearLab Corp will post ($2.75) earnings per share for the current fiscal year.

A number of analysts have issued reports on TEAR shares. HC Wainwright set a $12.00 target price on TearLab Corp and gave the stock a “buy” rating in a research report on Sunday, March 12th. Craig Hallum set a $6.00 price target on TearLab Corp and gave the company a “buy” rating in a research report on Saturday, March 11th. Feltl & Co. cut TearLab Corp from a “strong-buy” rating to a “buy” rating and set a $9.00 price target for the company. in a research report on Saturday, March 11th. Zacks Investment Research cut TearLab Corp from a “buy” rating to a “hold” rating in a research report on Tuesday. Finally, Rodman & Renshaw reduced their price target on TearLab Corp from $12.00 to $4.00 and set a “buy” rating for the company in a research report on Tuesday. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. The company has an average rating of “Buy” and an average target price of $5.05.

ILLEGAL ACTIVITY WARNING: “TearLab Corp (TEAR) Getting Somewhat Negative News Coverage, AlphaOne Reports” was posted by Sports Perspectives and is the sole property of of Sports Perspectives. If you are accessing this report on another website, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The legal version of this report can be accessed at https://sportsperspectives.com/2017/05/20/somewhat-critical-press-coverage-extremely-likely-to-affect-tearlab-corp-tear-share-price-updated-updated.html.

In related news, major shareholder Awm Investment Company, Inc. sold 327,674 shares of the company’s stock in a transaction dated Thursday, March 30th. The shares were sold at an average price of $3.20, for a total transaction of $1,048,556.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. 11.60% of the stock is currently owned by corporate insiders.

TearLab Corp Company Profile

TearLab Corporation is an in-vitro diagnostic company. The Company has commercialized a tear testing platform, the TearLab Osmolarity System, which enables eye care practitioners to test for sensitive and specific biomarkers using nanoliters of tear film at the point-of-care. The Company, through its subsidiary TearLab Research, Inc, develops technologies to enable eye care practitioners to test a range of biomarkers (chemistries, metabolites, genes and proteins) at the point-of-care.

12 Month Chart for NASDAQ:TEAR

Receive News & Ratings for TearLab Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TearLab Corp and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply